A Phase 2 interventional study of UFOX + Cetuximab and FOLFOX4 + Cetuximab in Previously Untreated Metastatic Colorectal Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 57 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an exploratory study to compare activity and safety in 400 patients with previously untreated metastatic carcinoma of the colon treated with UFOX (a combination regimen of UFT® (Tegafur plus Uracil), Oxaliplatin, Folinic Acid) plus Cetuximab or FOLFOX-4 (a combination regimen of 5 Fluorouracil (5-FU), Oxaliplatin and Folinic Acid) plus Cetuximab)
10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's enrollment of 302 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
UFOX + Cetuximab
Drug: UFOX + Cetuximab
FOLFOX4 + Cetuximab
Drug: FOLFOX4 + Cetuximab
Drug page: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22) * Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks) * Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21 * Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21
Drug page: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22) * Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks) * 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16 * Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16
Progression-free Survival (PFS)
Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria
Time frame: Time from randomization to disease progression, death, or last tumor assessment reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
Best Overall Response (BOR)
BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as "Disappearance of all target lesions plus disappearance of all non-target lesions \& without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as "At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later
Time frame: Evaluations were performed every 8 weeks until disease progression, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
Overall Survival (OS)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Time frame: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
Overall Survival (OS)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Time frame: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 31 Aug 2011
Quality of Life (QOL) Functional Assessment of Cancer Therapy-Colorectal (FACT-C)
All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0="Not at all" to 4="Very much". For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL.
Time frame: At baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. Cycles were 4 weeks long unless dosing delays
QOL EuroQuol-5D (EQ-5D) Health Outcome Questionnaire
The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL.
Time frame: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
QOL Therapy Preference Questionnaire (TPQ)
TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic.
Time frame: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
Treatment Impact on Social Daily Living and Health Care Resource Utilization
Non-protocol medical care visits and consultations
Time frame: From randomisation until final visit, reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009
Safety - Number of Patients Experiencing Any Adverse Event
Please refer to Adverse Events section for details of individual serious adverse events and other adverse events
Time frame: Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
First subject randomised 12 February 2007, last subject randomised 30 June 2008. Cut off date was 30th June 2009
| Milestone | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Started | 152 | 150 |
| Completed | 150 | 150 |
| Not completed | 2 | 0 |
| Withdrew: Subject on treatment | 1 | 0 |
| Withdrew: Subject in survival follow-up | 1 | 0 |
Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria
| months | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Progression-free Survival (PFS) | 6.6 (5.6 to 7.2) | 8.2 (7.5 to 9.2) |
BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as "Disappearance of all target lesions plus disappearance of all non-target lesions \& without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as "At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later
| percentage of participants | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Best Overall Response (BOR) | 37.5 (29.8 to 45.7) | 51.3 (43.0 to 59.6) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
| months | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Overall Survival (OS) | 12.9 (11.5 to 15.8) | 15.5 (12.6 to 18.1) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
| months | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Overall Survival (OS) | 16.8 (13.9 to 18.5) | 18.4 (15.3 to 20.9) |
All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0="Not at all" to 4="Very much". For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL.
| scores on a scale | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Baseline | 98.22 ± 1.725 | 96.45 ± 1.749 |
| Cycle 3 | 95.41 ± 1.735 | 95.89 ± 1.806 |
| Cycle 6 | 94.75 ± 2.090 | 94.70 ± 2.126 |
The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL.
| scores on a scale | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Baseline | 0.747 ± 0.021 | 0.734 ± 0.021 |
| Cycle 3 | 0.782 ± 0.021 | 0.758 ± 0.022 |
| Cycle 6 | 0.758 ± 0.026 | 0.771 ± 0.026 |
TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic.
| percentage of participants | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Baseline: Does not increase your risk of infection | 18 | 16 |
| Baseline: Does not interfere with daily activities | 17 | 15 |
| Baseline: Does not make you vomit | 4 | 14 |
| Baseline: Does not give you diarrhea | 9 | 5 |
| Cycle 3: Does not increase your risk of infection | 15 | 15 |
| Cycle 3: Does not interfere with daily activities | 10 | 11 |
| Cycle 3: Does not make you vomit | 4 | 10 |
| Cycle 3: Does not give you diarrhea | 15 | 4 |
Non-protocol medical care visits and consultations
| visits or consultations | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Emergency room visit | 34 | 26 |
| Hospital oupatient clinic visit | 40 | 35 |
| Practice visit | 71 | 159 |
| Home visit | 15 | 130 |
| General Practitioner consultation | 65 | 124 |
| Specialist consultation | 62 | 84 |
| Nurse consultation | 15 | 123 |
| Other consultation | 19 | 18 |
Please refer to Adverse Events section for details of individual serious adverse events and other adverse events
| participants | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| Safety - Number of Patients Experiencing Any Adverse Event | 151 | 149 |
Collected over Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Dec 2006, until cut off date, 30 Jun 2009. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UFOX + Cetuximab | — | 52/151 (34.4%) | 151/151 (100%) |
| FOLFOX4 + Cetuximab | — | 48/150 (32%) | 146/150 (97.3%) |
| Event | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 13/151 | 4/150 |
| VomitingGastrointestinal disorders | 9/151 | 3/150 |
| PyrexiaGeneral disorders | 3/151 | 8/150 |
| Central line infectionInfections and infestations | 1/151 | 5/150 |
| Abdominal painGastrointestinal disorders | 5/151 | 4/150 |
| IleusGastrointestinal disorders | 5/151 | 2/150 |
| Intestinal obstructionGastrointestinal disorders | 5/151 | 2/150 |
| General physical health deteriorationGeneral disorders | 0/151 | 4/150 |
| NauseaGastrointestinal disorders | 4/151 | 0/150 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/151 | 2/150 |
| Event | UFOX + Cetuximab | FOLFOX4 + Cetuximab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 79/151 | 72/150 |
| NauseaGastrointestinal disorders | 67/151 | 55/150 |
| NeutropeniaBlood and lymphatic system disorders | 10/151 | 65/150 |
| RashSkin and subcutaneous tissue disorders | 63/151 | 47/150 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 40/151 | 45/150 |
| ParaesthesiaNervous system disorders | 38/151 | 43/150 |
| VomitingGastrointestinal disorders | 40/151 | 32/150 |
| AnorexiaMetabolism and nutrition disorders | 40/151 | 36/150 |
| FatigueGeneral disorders | 38/151 | 38/150 |
| ThrombocytopeniaBlood and lymphatic system disorders | 33/151 | 37/150 |
| Age, Continuous(years) | UFOX + Cetuximab | FOLFOX4 + Cetuximab | Total |
|---|---|---|---|
| Mean | 60.1 ± 10.01 | 61 ± 11.04 | 60.5 ± 10.53 |
| Age, Customized(participants) | UFOX + Cetuximab | FOLFOX4 + Cetuximab | Total |
|---|---|---|---|
| <65 years | 93 | 84 | 177 |
| >=65 years | 57 | 66 | 123 |
| Missing | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | UFOX + Cetuximab | FOLFOX4 + Cetuximab | Total |
|---|---|---|---|
| Female | 57 | 55 | 112 |
| Male | 95 | 95 | 190 |
| Region of Enrollment(participants) | UFOX + Cetuximab | FOLFOX4 + Cetuximab | Total |
|---|---|---|---|
| Hong Kong | 7 | 4 | 11 |
| Greece | 9 | 5 | 14 |
| Thailand | 7 | 9 | 16 |
| Austria | 13 | 9 | 22 |
| Italy | 28 | 33 | 61 |
| France | 6 | 8 | 14 |
| Mexico | 4 | 0 | 4 |
| Argentina | 5 | 6 | 11 |
| Brazil | 5 | 9 | 14 |
| Poland | 30 | 27 | 57 |
| Belgium | 5 | 7 | 12 |
| Australia | 6 | 5 | 11 |
| Germany | 27 | 28 | 55 |
The record gives a start of Feb 2007, a primary completion of Jun 2009 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab
Merck KGaA, Darmstadt, Germany →